By Nate Raymond
BOSTON, Dec 26 (Reuters) - The former chief executive of Insys Therapeutics Inc has agreed to plead guilty to participating in a scheme to bribe doctors to prescribe a powerful opioid medication in order to boost its sales, U.S. prosecutors said on Wednesday.
Michael Babich, who resigned as the Arizona-based drugmaker's CEO in 2015 and was due to face trial next month, has agreed to plead guilty to conspiracy and mail fraud charges, federal prosecutors in Boston disclosed in a court filing.
The terms of Babich's plea deal were not disclosed, and it was unclear whether he would agree to cooperate with prosecutors and testify at that trial, as has another former Insys executive who recently pleaded guilty to racketeering conspiracy.
Prosecutors requested a Jan. 9 plea hearing. A lawyer for Babich, 42, declined to comment.
The case centers on Subsys, Insys' under-the-tongue spray for managing pain in cancer patients. It contains fentanyl, an opioid 100 times stronger than morphine.
Prosecutors allege that from 2012 to 2015, Kapoor, Babich and others conspired to bribe doctors in exchange for prescribing their patients Subsys. Prosecutors said they also defrauded insurers into paying for Subsys.
Prosecutors allege Insys paid doctors kickbacks in the form of fees to participate in speaker programs ostensibly meant to educate medical professionals about Subsys that were actually shams.
The case has been brought amid a national opioid addiction epidemic. According to the U.S. Centers for Disease Control and Prevention, opioids were involved in around 47,600 overdose deaths in 2017.
Babich, who was originally indicted in 2016, is married to a former Insys sales representative, Natalie Babich, who in 2017 pleaded guilty to conspiring to pay kickbacks and became a government witness.
She testified this month at the trial of Christopher Clough, a former physician assistant in New Hampshire accused of accepting kickbacks from Insys. A federal jury in Concord, New Hampshire convicted Clough on Dec. 18.
In August, Insys said it had agreed to settle a related U.S. Justice Department probe for at least $150 million.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.